The risk or severity of adverse effects can be increased when Naproxen is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Isoflurophate. The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Methylprednisolone. The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Balsalazide is combined with Methylprednisolone. The metabolism of Methylprednisolone can be decreased when combined with Diltiazem. The risk or severity of adverse effects can be increased when Nepafenac is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A. The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Indinavir. The risk or severity of adverse effects can be increased when Indobufen is combined with Methylprednisolone. The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Methylprednisolone. The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Methylprednisolone. The metabolism of Methylprednisolone can be decreased when combined with Olaparib. The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Methylprednisolone. The metabolism of Methylprednisolone can be decreased when combined with Fluconazole. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rindopepimut. The risk or severity of adverse effects can be increased when Azelastine is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Estradiol. The serum concentration of Methylprednisolone can be increased when it is combined with Dasatinib. The risk or severity of adverse effects can be increased when Adapalene is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Dienestrol. Methylprednisolone may increase the hypokalemic activities of Amphotericin B. The risk or severity of adverse effects can be increased when Lisofylline is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Tinoridine is combined with Methylprednisolone. The therapeutic efficacy of Gusperimus can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trovafloxacin. Methylprednisolone may increase the immunosuppressive activities of Tofacitinib. Digoxin may decrease the cardiotoxic activities of Methylprednisolone. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gatifloxacin. Roflumilast may increase the immunosuppressive activities of Methylprednisolone. The risk or severity of adverse effects can be increased when Sulindac is combined with Methylprednisolone. Ouabain may decrease the cardiotoxic activities of Methylprednisolone. The metabolism of Methylprednisolone can be decreased when combined with Delavirdine. The metabolism of Methylprednisolone can be decreased when combined with Ziprasidone. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with INGN 201. The metabolism of Methylprednisolone can be decreased when combined with Nilotinib. The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Cobicistat. The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Methylprednisolone. The serum concentration of Cerivastatin can be increased when it is combined with Methylprednisolone. Methylprednisolone may increase the immunosuppressive activities of Fingolimod. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rabies virus inactivated antigen, A. Methylprednisolone may increase the hypokalemic activities of Indapamide. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Palbociclib. The therapeutic efficacy of Gliquidone can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Methylprednisolone. The therapeutic efficacy of Voglibose can be decreased when used in combination with Methylprednisolone. The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Oxaprozin is combined with Methylprednisolone. The therapeutic efficacy of Glibornuride can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tubocurarine. Methylprednisolone may increase the hypokalemic activities of Hydrochlorothiazide. The metabolism of Methylprednisolone can be decreased when combined with Sildenafil. The risk or severity of adverse effects can be increased when Floctafenine is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Grepafloxacin. The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Fenoprofen is combined with Methylprednisolone. The therapeutic efficacy of Sulodexide can be decreased when used in combination with Methylprednisolone. The serum concentration of Methylprednisolone can be decreased when it is combined with Lumacaftor. Trastuzumab may increase the cardiotoxic activities of Methylprednisolone. The bioavailability of Methylprednisolone can be decreased when combined with Magnesium Hydroxide. The risk or severity of adverse effects can be increased when Apremilast is combined with Methylprednisolone. Methylprednisolone may increase the hypokalemic activities of Chlorothiazide. The risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Mesalazine is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Ceritinib. The serum concentration of Methylprednisolone can be increased when it is combined with Stiripentol. The risk or severity of adverse effects can be increased when Fenbufen is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Fusidic Acid. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rivastigmine. The bioavailability of Methylprednisolone can be decreased when combined with Bismuth Subcitrate. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rubella virus vaccine. Methylprednisolone may increase the hypokalemic activities of Methyclothiazide. The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Nefazodone. The therapeutic efficacy of Glyburide can be decreased when used in combination with Methylprednisolone. The serum concentration of Methylprednisolone can be decreased when it is combined with St. John's Wort. Methylprednisolone may increase the fluid retaining activities of Fluoxymesterone. The risk or severity of adverse effects can be increased when Loxoprofen is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Piroxicam is combined with Methylprednisolone. Colestipol can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. The bioavailability of Methylprednisolone can be decreased when combined with Magnesium Trisilicate. Methylprednisolone may increase the fluid retaining activities of GLPG-0492. The serum concentration of Methylprednisolone can be increased when it is combined with Equol. The risk or severity of adverse effects can be increased when Suprofen is combined with Methylprednisolone. The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tecemotide. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Gallamine Triethiodide. Methylprednisolone may increase the hypokalemic activities of Torasemide. The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Methanesulfonyl Fluoride. Digitoxin may decrease the cardiotoxic activities of Methylprednisolone. The bioavailability of Methylprednisolone can be decreased when combined with Calcium Carbonate. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Minaprine. Methylprednisolone may increase the fluid retaining activities of Testosterone Propionate. The risk or severity of adverse effects can be increased when Salsalate is combined with Methylprednisolone. The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Methylprednisolone. The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Methallenestril. The therapeutic efficacy of Glipizide can be decreased when used in combination with Methylprednisolone. The risk or severity of adverse effects can be increased when Metamizole is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Ranolazine. The risk or severity of adverse effects can be increased when Lisuride is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Lornoxicam is combined with Methylprednisolone. The bioavailability of Methylprednisolone can be decreased when combined with Almasilate. The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Mestranol. The metabolism of Methylprednisolone can be decreased when combined with Atomoxetine. The therapeutic efficacy of Nateglinide can be decreased when used in combination with Methylprednisolone. The serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fleroxacin. The risk or severity of adverse effects can be increased when Etoricoxib is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pazufloxacin. Methylprednisolone may increase the anticoagulant activities of Warfarin. The serum concentration of Methylprednisolone can be increased when it is combined with Simeprevir. Cholestyramine can cause a decrease in the absorption of Methylprednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Ketorolac is combined with Methylprednisolone. The serum concentration of Methylprednisolone can be increased when it is combined with Itraconazole. The risk or severity of adverse effects can be increased when Meloxicam is combined with Methylprednisolone. The therapeutic efficacy of Liraglutide can be decreased when used in combination with Methylprednisolone. The therapeutic efficacy of Castanospermine can be decreased when used in combination with Methylprednisolone. The therapeutic efficacy of Pramlintide can be decreased when used in combination with Methylprednisolone. The therapeutic efficacy of Alogliptin can be decreased when used in combination with Methylprednisolone.